514 related articles for article (PubMed ID: 16188302)
1. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M
Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302
[TBL] [Abstract][Full Text] [Related]
2. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
van der Velde NM; Mourits MJ; Arts HJ; de Vries J; Leegte BK; Dijkhuis G; Oosterwijk JC; de Bock GH
Int J Cancer; 2009 Feb; 124(4):919-23. PubMed ID: 19035463
[TBL] [Abstract][Full Text] [Related]
3. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.
Meeuwissen PA; Seynaeve C; Brekelmans CT; Meijers-Heijboer HJ; Klijn JG; Burger CW
Gynecol Oncol; 2005 May; 97(2):476-82. PubMed ID: 15863147
[TBL] [Abstract][Full Text] [Related]
4. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective.
Woodward ER; Sleightholme HV; Considine AM; Williamson S; McHugo JM; Cruger DG
BJOG; 2007 Dec; 114(12):1500-9. PubMed ID: 17903229
[TBL] [Abstract][Full Text] [Related]
5. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study.
Bosse K; Rhiem K; Wappenschmidt B; Hellmich M; Madeja M; Ortmann M; Mallmann P; Schmutzler R
Gynecol Oncol; 2006 Dec; 103(3):1077-82. PubMed ID: 16904167
[TBL] [Abstract][Full Text] [Related]
6. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.
Schwartz MD; Kaufman E; Peshkin BN; Isaacs C; Hughes C; DeMarco T; Finch C; Lerman C
J Clin Oncol; 2003 Nov; 21(21):4034-41. PubMed ID: 14581427
[TBL] [Abstract][Full Text] [Related]
7. [Screening pelvic tumours for hereditary risk of ovarian neoplasms, a cancer center experience].
Taïeb S; Rocourt N; Narducci F; Leblanc E; Adenis C; Fournier C; Doutrelant P; Peyrat JP; Vennin P
Bull Cancer; 2011 Feb; 98(2):113-9. PubMed ID: 21339094
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study.
Gaarenstroom KN; van der Hiel B; Tollenaar RA; Vink GR; Jansen FW; van Asperen CJ; Kenter GG
Int J Gynecol Cancer; 2006; 16 Suppl 1():54-9. PubMed ID: 16515568
[TBL] [Abstract][Full Text] [Related]
9. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.
Cortesi L; De Matteis E; Toss A; Marchi I; Medici V; Contu G; Xholli A; Grandi G; Cagnacci A; Federico M
Oncology; 2017; 93(6):377-386. PubMed ID: 28848147
[TBL] [Abstract][Full Text] [Related]
11. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers.
Evans DG; Gaarenstroom KN; Stirling D; Shenton A; Maehle L; Dørum A; Steel M; Lalloo F; Apold J; Porteous ME; Vasen HF; van Asperen CJ; Moller P
J Med Genet; 2009 Sep; 46(9):593-7. PubMed ID: 18413372
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
[TBL] [Abstract][Full Text] [Related]
13. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
[No Abstract] [Full Text] [Related]
14. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system.
Stirling D; Evans DG; Pichert G; Shenton A; Kirk EN; Rimmer S; Steel CM; Lawson S; Busby-Earle RM; Walker J; Lalloo FI; Eccles DM; Lucassen AM; Porteous ME
J Clin Oncol; 2005 Aug; 23(24):5588-96. PubMed ID: 16110018
[TBL] [Abstract][Full Text] [Related]
15. Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.
Chen Y; Bancroft E; Ashley S; Arden-Jones A; Thomas S; Shanley S; Saya S; ; Wakeling E; Eeles R
Fam Cancer; 2014 Jun; 13(2):197-203. PubMed ID: 24389956
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of women at high risk for hereditary ovarian cancer is inefficient.
Oei AL; Massuger LF; Bulten J; Ligtenberg MJ; Hoogerbrugge N; de Hullu JA
Br J Cancer; 2006 Mar; 94(6):814-9. PubMed ID: 16495917
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
18. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
Fishman DA; Cohen L; Blank SV; Shulman L; Singh D; Bozorgi K; Tamura R; Timor-Tritsch I; Schwartz PE
Am J Obstet Gynecol; 2005 Apr; 192(4):1214-21; discussion 1221-2. PubMed ID: 15846205
[TBL] [Abstract][Full Text] [Related]
19. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.
Carcangiu ML; Peissel B; Pasini B; Spatti G; Radice P; Manoukian S
Am J Surg Pathol; 2006 Oct; 30(10):1222-30. PubMed ID: 17001151
[TBL] [Abstract][Full Text] [Related]
20. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
